BRPI0514823A - modificações cristalinas de n-alfa-(2, 4, 6-triisopropilfenilsulfonil)-3-hidroxiamidino-(l)-feni lalanina 4-etoxicarbonilpiperazida e/ou sais do mesmo - Google Patents

modificações cristalinas de n-alfa-(2, 4, 6-triisopropilfenilsulfonil)-3-hidroxiamidino-(l)-feni lalanina 4-etoxicarbonilpiperazida e/ou sais do mesmo

Info

Publication number
BRPI0514823A
BRPI0514823A BRPI0514823-5A BRPI0514823A BRPI0514823A BR PI0514823 A BRPI0514823 A BR PI0514823A BR PI0514823 A BRPI0514823 A BR PI0514823A BR PI0514823 A BRPI0514823 A BR PI0514823A
Authority
BR
Brazil
Prior art keywords
salts
crystalline modifications
ethoxycarbonylpiperazide
triisopropylphenylsulfonyl
hydroxyamidino
Prior art date
Application number
BRPI0514823-5A
Other languages
English (en)
Inventor
Alfons Grunenberg
Jana Lenz
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex Ag filed Critical Wilex Ag
Publication of BRPI0514823A publication Critical patent/BRPI0514823A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

MODIFICAçõES CRISTALINAS DE N-ALFA-(2,4,6-TRIISOPROPILFENILSULFONIL)-3-HIDROXIAMIDI NO-(L)-FENILALANINA 4-ETOXICARBONILPIPERAZIDA E/OU SAIS DO MESMO. Refere-se às novas modificações cristalinas de N-<244>-(2,4,6-triisopropilfenilsulfonil)-3-hidroxiamidino-(L)-fenilalanin a 4-etoxicarbonilpiperazida e/ou sais do mesmo, que podem ser empregadas como agentes farmacêuticos, e às composições farmacêuticas e usos farmacêuticos compreendendo essas novas modificações cristalinas.
BRPI0514823-5A 2004-11-26 2005-11-24 modificações cristalinas de n-alfa-(2, 4, 6-triisopropilfenilsulfonil)-3-hidroxiamidino-(l)-feni lalanina 4-etoxicarbonilpiperazida e/ou sais do mesmo BRPI0514823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004057195A DE102004057195A1 (de) 2004-11-26 2004-11-26 Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
PCT/EP2005/012589 WO2006056448A1 (de) 2004-11-26 2005-11-24 KRISTALLINE MODIFIKATIONEN VON N-α-(2,4,6-TRIISOPROPYLPHENYLSULFONYL)-3-HYDROXYAMIDINO-(L)-PHENYLALANIN-4-ETHOXYCARBONYLPIPERAZID UND/ODER SALZEN DAVON

Publications (1)

Publication Number Publication Date
BRPI0514823A true BRPI0514823A (pt) 2008-06-24

Family

ID=35811673

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514823-5A BRPI0514823A (pt) 2004-11-26 2005-11-24 modificações cristalinas de n-alfa-(2, 4, 6-triisopropilfenilsulfonil)-3-hidroxiamidino-(l)-feni lalanina 4-etoxicarbonilpiperazida e/ou sais do mesmo

Country Status (17)

Country Link
US (2) US7713980B2 (pt)
EP (1) EP1833810B1 (pt)
JP (1) JP5054538B2 (pt)
KR (2) KR101455788B1 (pt)
CN (1) CN1989118B (pt)
AU (1) AU2005308977B2 (pt)
BR (1) BRPI0514823A (pt)
CA (1) CA2581959C (pt)
DE (1) DE102004057195A1 (pt)
DK (1) DK1833810T3 (pt)
ES (1) ES2645567T3 (pt)
HU (1) HUE037259T2 (pt)
MX (1) MX2007001420A (pt)
PL (1) PL1833810T3 (pt)
PT (1) PT1833810T (pt)
RU (1) RU2388754C2 (pt)
WO (1) WO2006056448A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103040815B (zh) * 2011-10-13 2014-12-10 中国科学院上海药物研究所 一类2，4，6-三异丙基苯类化合物在制备治疗糖尿病的药物中的用途
CN105566327A (zh) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
CA2997671A1 (en) * 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
GEP20237494B (en) * 2018-10-31 2023-04-10 Servier Lab Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
US11052073B1 (en) 2020-03-10 2021-07-06 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
EP4347593A4 (en) * 2021-06-04 2025-10-01 Repare Therapeutics Inc CRYSTALLINE FORMS, COMPOSITIONS CONTAINING THEM AND METHODS OF USE THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791196A (en) * 1986-09-26 1988-12-13 Sankyo Company Limited Crystalline cephem carboxylic acid addition salt
RU2171811C2 (ru) * 1989-05-29 2001-08-10 Такара Сузо Ко., Лтд., (Jp), Ниппон Каяку Кабусики Кайся КРИСТАЛЛИЧЕСКИЙ ТРИГИДРОХЛОРИД ДЕОКСИСПЕРГУАЛИНА В β-ФОРМЕ, ОБЛАДАЮЩИЙ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
NZ273129A (en) * 1993-08-19 1996-08-27 Merck & Co Inc 4"-deoxy-4"-epi-methylamino avermectin b1a/b1b benzoic acid salt hemihydrate; pesticidal compositions
JP4414652B2 (ja) * 2001-03-21 2010-02-10 ヴィレックス アクチェンゲゼルシャフト ウロキナーゼ阻害剤
SI21137A (sl) 2002-01-24 2003-08-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Derivati azafenilalanina
CH695999A5 (de) 2002-02-28 2006-11-15 Wilex Ag Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten.
WO2004011449A2 (de) 2002-07-25 2004-02-05 Wilex Ag Verfahren zur herstellung von phenylalanin-derivaten
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE102004045720A1 (de) * 2004-09-21 2006-03-23 Wilex Ag Stabile Dosierungsform von Phenylalanin-Derivaten

Also Published As

Publication number Publication date
DE102004057195A1 (de) 2006-06-01
RU2007123712A (ru) 2009-01-10
JP5054538B2 (ja) 2012-10-24
MX2007001420A (es) 2007-04-19
KR20130066700A (ko) 2013-06-20
HUE037259T2 (hu) 2018-08-28
ES2645567T3 (es) 2017-12-05
CA2581959A1 (en) 2006-06-01
US20100266679A1 (en) 2010-10-21
CN1989118B (zh) 2012-11-14
US8492385B2 (en) 2013-07-23
RU2388754C2 (ru) 2010-05-10
PL1833810T3 (pl) 2018-01-31
EP1833810A1 (de) 2007-09-19
EP1833810B1 (de) 2017-08-30
PT1833810T (pt) 2017-12-11
KR101455788B1 (ko) 2014-11-04
KR20070083507A (ko) 2007-08-24
US20080058346A1 (en) 2008-03-06
WO2006056448A1 (de) 2006-06-01
AU2005308977A1 (en) 2006-06-01
CA2581959C (en) 2013-08-06
DK1833810T3 (da) 2017-12-04
KR101311329B1 (ko) 2013-09-25
CN1989118A (zh) 2007-06-27
US7713980B2 (en) 2010-05-11
JP2008521764A (ja) 2008-06-26
AU2005308977B2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
PA8582601A1 (es) Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
CR9602A (es) Nuevos derivados de 2,4-dianilinpirimidinas, su preparacion, como medicamentos, composiciones farmaceuticas y particularmente como inhibidores de ikk
GT200600518A (es) Derivados de pirimidina
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
PA8623001A1 (es) Compuestos de quinolina sustituidos
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac&#39;s, seu uso, composição farmacêutica e combinação
CR11507A (es) Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo y sus usos en terapia
ECSP088297A (es) 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-e]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA
CR10376A (es) Derivados de terfenil para el tratamiento de la enfermedad de alzheimer
SE0401342D0 (sv) Therapeutic compounds
BRPI0713132B8 (pt) compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UY30558A1 (es) Derivados de pirazol como agentes antiagregantes plaquetarios y antitromboticos
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
UY27658A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinación para el tratamiento de enfermedades
UY27656A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinación para el tratamiento de enfermedades
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
ECSP088761A (es) Nuevas combinaciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: WILEX AG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080117818/RJ DE 08/09/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 295/185

Ipc: C07D 295/185 (2006.01), C07D 295/205 (2006.01), A6

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2627 DE 11/05/2021 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]